Research Article
Sarcoid-Like Mediastinal Lymphadenopathy in Gynecologic Malignancy

Bilal H. Lashari,1 Megumi Asai,2 Gissele Randleman,3 Martha Sack,3 and Rajeshkumar Patel4

1Department of Internal Medicine, Abington Jefferson Health, Abington, PA, USA
2Department of Surgery, Abington Jefferson Health, Abington, PA, USA
3Department of Pathology, Abington Jefferson Health, Abington, PA, USA
4Pulmonary-Critical Care Medicine, Abington Jefferson Health, Abington, PA, USA

Correspondence should be addressed to Bilal H. Lashari; bilal.lashari@jefferson.edu

Received 23 September 2017; Revised 11 January 2018; Accepted 17 January 2018; Published 14 February 2018

1. Introduction
Granulomatous inflammation in lymph nodes can be attributable to nonspecific inflammation such as sarcoidosis or secondary to fungal and mycobacterial infection or foreign body reaction to respiratory inhalants [1]. It has been associated with neoplastic disease in regional and distant lymph nodes. It was described in association with Non-Small Cell Lung Cancer [2] and as high as 14% in Hodgkin disease [3]. The causes of this phenomenon are currently unknown.

Recent studies have indicated that granulomatous lymphadenitis may precede the development of and follow the resolution of a wide range of malignancy [4, 5]. Regional chest diseases and lymphoma understandably involve mediastinal and hilar lymph nodes. However, little data is available regarding the relationship of nonlocal malignancy and mediastinal lymphadenopathy, especially gynecologic malignancy [6].

2. Materials and Methods
After IRB approval (IRB Number 16-046) a retrospective review was performed of all endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) biopsies performed between 2013 and 2016 at our institution, with histologic findings of granuloma, histiocytes, and giant cells. All female patients with age greater than 18 were included. Patients with a history of sarcoidosis or fungal or mycobacterial infection were excluded. In addition, a patient with evidence of malignant cells on TBNA specimen were excluded. Our results revealed 65 patients with histologic diagnosis of a noncaseating granuloma on EBUS-TBNA. Five patients (7.69%) had a history of gynecologic malignancy. Two patients had evidence of PET-positive nodes on surveillance scans, which led directly to the examination. Our findings suggest that distant malignancies may cause granulomatous lymphadenitis, through yet undefined mechanisms. As such, patients with evidence of mediastinal lymphadenopathy could benefit from routine sampling and histologic examination to define the pathology in the correct clinical context.
examination of the mediastinum and hilar lymph nodes was conducted followed by transbronchial needle aspiration of lymph nodes >10 mm in short axis diameter. At least five passes were made per node.

4. Results

Our search yielded 65 patients with pathological diagnosis of noncaseating granuloma. Tissue staining for acid fast organisms and fungi were negative in all patients. Pathological analysis of EBUS-TBNA samples did not identify malignant cells.

Five patients had a history of gynecologic malignancy. The malignancies and characteristics of these patients are described in Table I. All five were found to have mediastinal lymphadenopathy on surveillance CT scans as part of regular follow-up.

Two patients had a history of serous ovarian carcinoma and FIGO stages IIIA and IIIB at diagnosis, underwent appropriate therapy, and had been disease-free for two years. Of these, one patient had PET-positive nodes in right hila, with increased metabolic activity with an SUV max of 3.7; this patient had stage IIIB disease and had been treated with IV Taxol and Intraperitoneal Cisplatin and Taxol after undergoing TLH and BSO. The second patient did not have a PET scan; she had stage IIIA disease at diagnosis, two years before the diagnosis of mediastinal lymphadenopathy and had successfully undergone TAH-BSO and subsequent chemotherapy with Taxol-Cisplatin IV, neither patient had any documented mediastinal lymphadenopathy on initial staging CT scan.

One patient had FIGO IA Endometrial Adenocarcinoma diagnosed a year prior to PET-positive bilateral hilar lymphadenopathy. PET was remarkable for bilateral hilar uptake, with SUV max in representative left hilar nodes at 6.6, infracarinal node at 6.9, and right hilar node at 6.2. This patient had bilateral lymphadenopathy evident on initial staging CT, and sampling was performed for staging purposes. She had undergone TLH and BSO and was not recommended chemotherapy based on the localized nature of disease.

Another patient had a remote history of FIGO IC Endometrial Adenocarcinoma and was found to have right hilar lymphadenopathy on CT imaging, without PET scan four years after completion of treatment. Initial staging CT was negative for hilar lymphadenopathy, and chemotherapy regimen for this patient was unavailable.

The last patient had a remote serous fallopian carcinoma and FIGO IIIC and subsequently developed mediastinal lymphadenopathy found on CT. PET scan and chemotherapy regimen was not available for this patient.

No patient had radiologic evidence of parenchymal lung disease during their evaluation. All patients remained clinically and radiographically stable from a respiratory standpoint.

5. Discussion

A sarcoïd-like reaction is caused by a multitude of reasons including but not limited to infection (fungal, mycobacterial), autoimmune disorders, interstitial lung disease, chemotherapy, and chemical agents. Histology in granulomatous lymphadenitis is characterized by scattered small epithelioid granulomas with a sparse arrangement of epithelioid cells and accompanying lymphocytic infiltrate among granuloma cells [7]. Sarcoïd-like reaction as a tumor-related response was first described in 1917 by Herxheimer, in five patients [8]. It has been reported as frequently as 4-5% of all carcinomas. Approximately 14% of patients with Hodgkin disease and 7.3% of Non-Hodgkin lymphoma have sarcoïd-like lymphadenopathy. In one report almost 50% of patients with Seminoma have this finding [9]. In most malignancies, the granulomatous reaction is seen near the tumor cells [9]. There are case reports of distant nonmetastatic granulomatous lymphadenopathy in association with lung and gastrointestinal malignancies [10] and a range of solid tumors, by Grados et al. [11]. Our case series of granulomatous mediastinal lymphadenitis at a site remote from the location of primary gynecological malignancy without evidence of metastatic disease is unique in that sense.

It has been postulated that granuloma formation may play a role in host defense against metastasis [9]. Development of reactive granulomas in local lymph node groups draining the area occurs as tumor antigens are exposed to T cells after necrosis or tumor cell lysis. This can explain regional lymphadenitis but cannot explain the same phenomenon in remote lymph node groups. Similarly, systemic stimulation of T cell immunity by tumor antigen may explain granulomatous reaction at a site distant from malignancy but would not describe localized mediastinal lymphadenopathy. DePew et al. published a case series of 1275 patients of which 154 were found to have granulomatous lymphadenitis and revealed a history of malignant disease in 7.7% of patients [12]. While the pathogenic mechanism of these findings remains unclear, it has been demonstrated that the presence of granuloma does not positively or adversely affect outcome in cancer patients [13]; it is, however, important to note that patients with sarcoïdosis have an increased risk of developing a malignancy [14].

The exact mechanism of our observation is unknown. One simple reason could be a T cell response to a tumor antigen, and if this is the case, it should be seen in most patients with cancer. Also, patients may have developed these reactions to chemotherapy, but this does not explain the localized occurrence in mediastinal and hilar lymph nodes. Micrometastatic disease with local T cell response can explain our findings as well. Lastly, these patients may have developed granulomatous lymphadenitis entirely independent of the disease, diagnosed incidentally during the surveillance CT or PET scan.

Our results demonstrate the importance of multidisciplinary approach as one of the emerging tools in cancer management. Gynecological oncology was introduced to the endobronchial ultrasound (EBUS) guided sampling of mediastinal and hilar lymph nodes, a tool completely foreign to this specialty [15]. EBUS-TBNA is now the standard of care in sampling lymph nodes for staging of small cell lung cancer [16]; it can also become a helpful tool for nonpulmonary malignancy.
| Age | Primary malignancy               | FIGO stage at diagnosis | Sampled LN station | PET scan | PET uptake | Initial chemotherapy | Lymphadenopathy on initial staging CT scan | Duration in which patient was followed after EBUS and remained disease-free |
|-----|---------------------------------|-------------------------|--------------------|----------|------------|----------------------|-------------------------------------------|--------------------------------------------------------------------------------|
| 66  | Endometrial Adenocarcinoma      | IA                      | 4R, 7, 12L         | Positive | Rhilum maximal SUV of 6.6. Infracarinal maximal SUV of 6.9. R hilum maximal SUV of 6.2 | No chemotherapy advised | Mediastinal lymphadenopathy present on initial staging CT | 2 years |
| 68  | Serous ovarian carcinoma        | IIIB                    | 7 and 11R          | Positive | R hilar maximal SUV of 3.7 | Taxol IV, Cisplatin intraperitoneal, and Taxol intraperitoneal | None | 1 year |
| 33  | Serous ovarian carcinoma        | IIIA                    | 4R, 7, 11R         | N/A      | N/A        | Taxol/Cisplatin chemotherapy | None | 3 years |
| 67  | Serous fallopian carcinoma      | IIIC                    | 4R, 7, 10R         | N/A      | N/A        | N/A | None | N/A |
| 58  | Endometrial Adenocarcinoma      | IC                      | 4R, 7, 11R         | N/A      | N/A        | None | None | 4 years |
6. Conclusion

Mediastinal and hilar granulomatous lymphadenitis can be seen in patients with gynecological malignancy without metastatic disease. The exact pathologic mechanisms for the development of this reaction are unclear. PET and CT scan can give a falsely positive impression of metastatic disease. EBUS-guided sampling of mediastinal and hilar lymph nodes can be a useful tool in the evaluation of patients with mediastinal lymphadenopathy to confirm or refute metastatic disease even in gynecological malignancy.

Disclosure

An abstract of the above study was presented at the American Thoracic Society Annual Meeting 2017 at Washington DC as a poster presentation.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] S. Asano, “Granulomatous lymphadenitis,” Journal of Clinical and Experimental Hematopathology, vol. 52, no. 1, pp. 1–16, 2012.
[2] D. P. Steinfort and L. B. Irving, “Sarcoidal reactions in regional lymph nodes of patients with non-small cell lung cancer: Incidence and implications for minimally invasive staging with endobronchial ultrasound,” Lung Cancer, vol. 66, no. 3, pp. 305–308, 2009.
[3] H. Brincker, “Sarcoid reactions in malignant tumours,” Cancer Treatment Reviews, vol. 13, no. 3, pp. 147–156, 1986.
[4] J. Askling, J. Grunewald, A. Eklund, G. Hillerdal, and A. Ekbom, “Increased risk for cancer following sarcoidosis,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 5, part 1, pp. 1668–1672, 1999.
[5] M. P. Kennedy, C. A. Jimenez, A. D. Mhatre, R. C. Morice, and G. A. Eapen, “Clinical implications of granulomatous inflammation detected by endobronchial ultrasound transbronchial needle aspiration in patients with suspected cancer recurrence in the mediastinum,” Journal of Cardiothoracic Surgery, vol. 3, no. 1, article no. 8, 2008.
[6] P. Mapelli, G. Mangili, M. Picchio et al., “Sarcoidosis mimicking metastatic gynaecological malignancies: a diagnostic and therapeutic challenge?” Revista Española de Medicina Nuclear e Imagen Molecular, vol. 32, no. 5, pp. 314–317, 2013.
[7] G. T. Williams and W. J. Williams, “Granulomatous inflammation: a review,” Journal of Clinical Pathology, vol. 36, no. 7, pp. 723–733, 1983.
[8] G. Heraheimer, “Uber Karzinom und Tuberkulose,” Zeitschrift für Tuberkulose, vol. 27, pp. 251–258, 1917.
[9] M. Pavic, P. Debourdeau, V. Vacelet, and H. Rouset, “Sarcoidosis and sarcoid reactions in cancer,” La Revue de Médecine Interne, vol. 29, no. 1, pp. 39–45, 2008.
[10] N. Blank, H.-M. Lorenz, A. D. Ho, and M. Witzens-Harig, “Sarcoidosis and the occurrence of malignant diseases,” Rheumatology International, vol. 34, no. 10, pp. 1433–1439, 2014.
[11] A. Grados, M. Ebb, E. Bernit et al., “Sarcoidosis occurring after solid cancer: a nonfortuitous association: report of 12 cases and review of the literature,” Medicine (United States), vol. 94, no. 28, article no. e928, 2015.
[12] Z. S. DePew, W. I. Gonsalves, A. C. Roden, A. O. Bungum, J. J. Mullon, and F. Maldonado, “Granulomatous inflammation detected by endobronchial ultrasound-guided transbronchial needle aspiration in patients with a concurrent diagnosis of cancer: a clinical conundrum,” Journal of Bronchology & Interventional Pulmonology, vol. 19, no. 3, pp. 176–181, 2012.
[13] H. B. Grosu, D. E. Ost, R. C. Morice et al., “Mediastinal granulomatous inflammation and overall survival in patients with a history of malignancy,” Annals of the American Thoracic Society, vol. 12, no. 10, pp. 1534–1541, 2015.
[14] M. Bonifazi, F. Bravi, S. Gasparini et al., “Sarcoidosis and cancer risk: Systematic review and meta-analysis of observational studies systematic review and meta-analysis of observational studies,” CHEST, vol. 147, no. 3, pp. 778–791, 2015.
[15] S. Dhooria, A. N. Aggarwal, D. Gupta, D. Behera, and R. Agarwal, “Utility and safety of endoscopic ultrasound with bronchoscope- guided fine-needle aspiration in mediastinal lymph node sampling: Systematic review and meta-analysis,” Respiratory Care, vol. 60, no. 7, pp. 1040–1050, 2015.
[16] F. C. Deterbeck, M. A. Jantz, M. Wallace, J. Vansteenkiste, and G. A. Silvestri, “Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition),” CHEST, vol. 132, supplement 3, pp. 202S–220S, 2007.